Results 131 to 140 of about 17,066 (197)

Impact of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors on intracranial atherosclerotic plaque characteristics and low density lipoprotein-cholesterol (LDL-C) reduction: a real-world observational study. [PDF]

PeerJ
Li Z, Li X, Zhang Y, Qi J, Ji L, Li S, Gu M, Liu Y, Zhang Y, Mei Y, Wang M, Zhou J, Su M, Zhu L, Deng Q.   +14 more
europepmc   +1 more source

Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9) to tackle central nervous system diseases: role as a promising approach. [PDF]

Eur J Med Res
Zheng X, Yuan W, Li L, Ma H, Zhu M, Li X, Feng X.   +6 more
europepmc   +1 more source

Dysregulation of FURIN and Other Proprotein Convertase Genes in the Progression from HPV Infection to Cancer. [PDF]

Int J Mol Sci
Izaguirre G, Zirou N, Meyers C.
europepmc   +1 more source

Proprotein convertase subtilisin/kexin type 9: a promising marker of cardiovascular risk in post-menopausal diabetic women in primary prevention. [PDF]

Front Med (Lausanne)
Rottura M, Barbieri MA, Siniscalchi C, Di Micco P, Drago SFA, Gigliotti De Fazio M, Cicero AFG, Fogacci F, Armentaro G, Sciacqua A, Arcoraci V, Irrera N, Imbalzano E.   +12 more
europepmc   +1 more source

A Pre-Clinical Study on the Use of the Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor PEP 2-8 to Mitigate Ischemic Injury in a Rat Marginal Donor Model. [PDF]

Int J Mol Sci
Grignano MA, Gregorini M, Barisione C, Ivaldo C, Verzola D, Rumeo N, Malabarba S, Mimmi MC, Montatixe Fonseca EC, Viglio S, Iadarola P, Islami T, Pattonieri EF, Ceccarelli G, Picciotto D, Pratesi G, Viazzi F, Stea ED, Arbustini E, Esposito P, Rampino T.   +20 more
europepmc   +1 more source

Correction: Ascorbic acid enhances low-density lipoprotein receptor expression by suppressing proprotein convertase subtilisin/kexin 9 expression. [PDF]

J Biol Chem
Wang D, Yang X, Chen Y, Gong K, Yu M, Gao Y, Wu X, Hu H, Liao C, Han J, Duan Y.   +10 more
europepmc   +1 more source

<i>Proprotein Convertase Subtilisin</i>/<i>Kexin Type 9</i> (<i>PCSK9</i>) Inhibitor Therapy Reduces the Level of DNA Damage in Patients with Heterozygous Familial Hypercholesterolemia. [PDF]

Int J Mol Sci
Woźniak E, Woźniak A, Pawlos A, Broncel M, Satała J, Bukowska B, Gorzelak-Pabiś P.   +6 more
europepmc   +1 more source

The proprotein convertase FURIN is a novel aneurysm predisposition gene impairing TGF-β signalling. [PDF]

Cardiovasc Res
He Z, IJpma AS, Vreeken D, Heijsman D, Rosier K, Verhagen HJM, de Bruin JL, Brüggenwirth HT, Roos-Hesselink JW, Bekkers JA, Huylebroeck DFE, van Beusekom HMM, Creemers JWM, Majoor-Krakauer D.   +13 more
europepmc   +1 more source

Efficacy and safety of different proprotein convertase subtilisin/kexin type 9 inhibitors in the general population and solid organ transplant recipients: a network meta-analysis. [PDF]

Front Pharmacol
Luo B, Sun Z, Luo H.
europepmc   +1 more source

The correlation between proprotein convertase subtilisin/kexin type 9 and adiponectin in the progression from prediabetes to type 2 diabetes mellitus. [PDF]

Sci Rep
Gu JX, Wang K, Zhang AM, Yin Y, Li SS, Zhang N, Qin L, Wang CY, Pei L, Jia M, Su M.   +10 more
europepmc   +1 more source